Clinical Outcomes With Pembrolizumab-Based Therapies in Recurrent/Refractory NSCLC After Chemoradiation and Consolidative Durvalumab - Delasos, Lukas; Wei, Wei; Hassan, Khaled A.; Pennell, Nathan A.; Patil, Pradnya; Stevenson, James (Clinical lung cancer, 2023)
Keywords: Checkpoint inhibitor; Immunotherapy; Locally advanced non-small cell lung cancer; Recurrent non–small-cell lung cancer; Stage III non-small cell lung cancer; ALK; RET; CRT; NSCLC; OS; Locally advanced non-small cell lung cancer; BRAF; EGFR; R/R; Immunotherapy; ERBB2; PD-L1; KRAS; Stage III non-small cell lung cancer; PFS; MET; PD-1; ROS1; Checkpoint inhibitor; Recurrent non–small-cell lung cancer